Volume 26, Number 9—September 2020
Dispatch
Emergence of pstS-Null Vancomycin-Resistant Enterococcus faecium Clone ST1478, Canada, 2013–2018
Table 1
Antimicrobial drug | % ST1478, n = 115 | % Non-ST1478, n = 493 | p value |
---|---|---|---|
Ampicillin | 100.0 | 100.0 | 1 |
Chloramphenicol | 10.4 | 1 | 0.0001 |
Ciprofloxacin | 100.0 | 100.0 | 1 |
Daptomycin | 13.0 | 3.9 | 0.0014 |
Erythromycin | 100.0 | 92.1 | 0.6068 |
HL gentamicin | 80.0 | 13.6 | 0.0001 |
Levfloxacin | 100.0 | 99.6 | 1 |
Linezolid | 1.7 | 0.4 | 0.1669 |
Nitrofurantoin | 16.5 | 35.9 | 0.002 |
Penicillin | 100.0 | 100.0 | 1 |
Quinupristin/dalfopristin | 0.9 | 8.5 | 0.0032 |
Rifampin | 95.7 | 90.1 | 0.7104 |
HL streptomycin | 15.7 | 39.8 | 0.0002 |
Tetracycline | 91.3 | 46.0 | 0.0001 |
Tigecycline | 0.9 | 0.4 | 0.4776 |
Vancomycin | 100.0 | 97.2 | 0.8835 |
*HL, high level; ST, sequence type.
Page created: May 29, 2020
Page updated: August 19, 2020
Page reviewed: August 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.